MINNEAPOLIS, May 15, 2019 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, today announced financial results for the quarter ended March 31, 2019 and provided a business update.
Business highlights of the first quarter of 2019 through recent weeks include:
- Helomics, Inc. and National Alopecia Areata Foundation signed a services agreement to provide next-generation patient registry for Alopecia Areata Research
- TumorGenesis and partner 48Hour Discovery received Alberta Innovates grant for development of novel cancer treatments
- Helomics contracted to provide CRO and Artificial Intelligence drug development services to SpeciCare for a precision medicine trial
- Helomics initiated a collaboration with Viome to determine role of gut microbiome in ovarian cancer
- Helomics merger completed on April 4, 2019
- Completed public offerings of $1.2 and $1.1 million
- Skyline Medical division completed sales in Saudi Arabia and Australia
- TumorGenesis identified key biomarkers that may be potential treatment approaches for thyroid cancer
- Skyline Medical division signed Taiwanese distribution agreement
- CEO Carl Schwartz invested $1.62 million into the company since November 2018
Dr. Carl Schwartz, Precision’s Chief Executive Officer commented, “2019 began as a very strong and highly productive year for Precision Therapeutics, with key execution across all aspects of our business. With the Helomics merger now complete, we have already begun seeing numerous collaborations take place, including an exciting and potentially rewarding partnership with Viome to study the link between the gut biome and ovarian cancer. In addition, we have entered into an alliance with the National Alopecia Areata Foundation to provide next generation patient registry for Alopecia Areata research and entered into an exciting alliance with SpeciCare to study innovative personalized medicine opportunities for cancer patients. These exciting relationships represent strong opportunities to potentially monetize our proprietary AI and data-driven precision medicine offerings along with our CRO services. Our TumorGenesis business continues to be at the forefront of new discovery in oncology and we were thrilled to announce that TumorGenesis participated with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program to commercialize TumorGenesis’ Oncology Discovery Platform Kits, in collaboration with 48HD’s to inform personalized treatment decisions in cancer treatments. Interest in our Skyline Medical division’s STREAMWAY system division continues to increase across the globe and we anticipate growth of that business as we expand our sales and marketing efforts globally.”
Financial Results
Revenue for the quarter ended March 31, 2019 was $255,000, compared with $412,000 for the same period of 2018, a 38 percent decrease year over year. Revenue included the sale of seven STREAMWAY systems and disposable supplies, three domestically and four internationally, compared to 16 sales of the system in the comparable period of 2018. Cost of sales was $74,000 in the first quarter of 2019, compared to $117,000 in Q1 2018. Gross profit margin remained steady at 71 percent both in the first quarters of 2019 and 2018. Operating expenses for the quarter ended March 31, 2019 increased by $179,000 compared with the comparable quarter of 2018. General and accounting expenses were approximately $1.5 million, compared to approximately $1.2 million during the same period of the previous year. Sales and marketing expenses remained relatively consistent at $554,216, compared to 550,538 during Q1 2018.
Cash balance as of March 31, 2019 was $1.1 million.
Conference Call
The company will host a conference call at 4:30 today to review these results. Participants are asked to preregister for the call through the following link http://dpregister.com/10131658. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Precision Therapeutics Inc., call. Following management’s formal remarks, there will be a question and answer session with equity analysts.
The conference call will also be available through a live webcast, which can be accessed via the following link: https://services.choruscall.com/links/aipt190515.html, which will also be available through the company’s website at: http://investors.skylinemedical.com/events-and-presentations.
A replay of the call will be available approximately one hour after the end of the call through June 15, 2019. The replay can be accessed via Precision’s website or by dialing 1-877-344-7529 (U.S.) or +1-412-317-0088 (international). The replay conference playback code is 10131658.
A webcast replay of the call will also be available approximately one hour after the end of the call through August 15, 2019. The replay can be accessed through the above links.
About Precision Therapeutics Inc.
Precision Therapeutics (Nasdaq: AIPT) operates through its three wholly owned subsidiaries, Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Precision’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Precision’s Skyline Medical subsidiary markets its patented and FDA cleared STREAMWAY System which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.precisiontherapeutics.com.
Forward-looking Statements
Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; and the market price of the Company’s common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Precision’s ability to implement its long range business plan for various applications of its technology; Precision’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Precision’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Precision’s financial position. See Precision’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.
Contacts:
Investor Relations
CORE IR
Bret Shapiro
(212) 896-1203
brets@coreir.com
Media
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378
PRECISION THERAPEUTICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| March 31, 2019 |
December 31, 2018 |
||||||
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash and Cash Equivalents | $ | 1,124,730 | $ | 162,152 | |||
| Accounts Receivable | 173,443 | 232,602 | |||||
| Notes Receivable (inclusive of $738,138 and $452,775 in advances to Helomics) | 1,801,479 | 497,276 | |||||
| Inventories | 289,023 | 241,066 | |||||
| Prepaid Expense and other assets | 265,584 | 318,431 | |||||
| Total Current Assets | 3,654,259 | 1,451,527 | |||||
| Notes Receivable | – | 1,112,524 | |||||
| Fixed Assets, net | 148,709 | 180,453 | |||||
| Intangibles, net | 950,049 | 964,495 | |||||
| Lease Right-of-Use Assets | 333,944 | – | |||||
| Total Assets | $ | 5,086,961 | $ | 3,708,999 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current Liabilities: | |||||||
| Accounts Payable | $ | 432,198 | $ | 445,689 | |||
| Note Payable – Bridge Loan Net of Discount of $646,524 and $969,786 | 1,812,037 | 1,327,942 | |||||
| Notes Payable – Net of Discount of $352,961 and $63,028 | 1,267,039 | 306,972 | |||||
| Accrued Expenses | 797,599 | 1,279,114 | |||||
| Derivative Liability | 353,210 | 272,745 | |||||
| Deferred Revenue | 20,929 | 23,065 | |||||
| Current Lease Liability | 78,819 | – | |||||
| Total Current Liabilities | 4,761,831 | 3,655,527 | |||||
| Lease Liability | 225,125 | – | |||||
| Total Liabilities | 5,016,956 | 3,655,527 | |||||
| Stockholders’ Equity: | |||||||
| Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 79,246 outstanding | 792 | 792 | |||||
| Common Stock, $.01 par value, 100,000,000 authorized, 17,360,144 and 14,091,748 outstanding | 173,601 | 140,917 | |||||
| Additional paid-in capital | 66,296,741 | 63,019,708 | |||||
| Accumulated Deficit | (66,401,129 | ) | (63,107,945 | ) | |||
| Total Stockholders’ Equity | 70,005 | 53,472 | |||||
| Total Liabilities and Stockholders’ Equity | $ | 5,086,961 | $ | 3,708,999 | |||
PRECISION THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS
(Unaudited)
| Three Months Ended March 31, | |||||||
| 2019 | 2018 | ||||||
| Revenue | $ | 255,241 | $ | 411,593 | |||
| Cost of goods sold | 73,717 | 117,343 | |||||
| Gross margin | 181,524 | 294,250 | |||||
| General and administrative expense | 1,497,945 | 1,241,961 | |||||
| Operations expense | 466,566 | 287,590 | |||||
| Sales and marketing expense | 554,216 | 550,538 | |||||
| Total operating loss | 2,337,203 | 1,785,839 | |||||
| Other income | 53,432 | 27,655 | |||||
| Other expense | 569,776 | 1,838 | |||||
| Loss on equity method investment | 439,637 | – | |||||
| Net loss attributable to common shareholders | $ | (3,293,184 | ) | $ | (1,760,022 | ) | |
| Loss per common share – basic and diluted | $ | (0.21 | ) | $ | (0.15 | ) | |
| Weighted average shares used in computation – basic and diluted | 15,731,517 | 11,383,217 | |||||
PRECISION THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Three Months Ended March 31, |
|||||||
| 2019 | 2018 | ||||||
| Cash flow from operating activities: | |||||||
| Net loss | $ | (3,293,184 | ) | $ | (1,760,022 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Loss on equity method investment | 439,637 | – | |||||
| Depreciation and amortization | 39,526 | 18,167 | |||||
| Vesting expense for stock options | 263,600 | 226,387 | |||||
| Amortization of debt discount | 468,564 | – | |||||
| Loss on valuation of equity-linked instruments | 19,408 | – | |||||
| Changes in assets and liabilities: | |||||||
| Accounts receivable | 59,159 | (104,265 | ) | ||||
| Inventories | (47,957 | ) | (7,511 | ) | |||
| Prepaid expense and other assets | (3,273 | ) | 81,661 | ||||
| Accounts payable | (13,491 | ) | 45,847 | ||||
| Accrued expenses | 21,494 | (226,775 | ) | ||||
| Deferred revenue | (2,136 | ) | 32,193 | ||||
| Net cash used in operating activities: | (2,048,653 | ) | (1,694,318 | ) | |||
| Cash flow from investing activities: | |||||||
| Redemption of certificates of deposit | – | 244,971 | |||||
| Advance on notes receivable | (631,316 | ) | (42,524 | ) | |||
| Purchase of fixed assets | – | (32,789 | ) | ||||
| Transfer of fixed assets to inventory | 9,863 | – | |||||
| Acquisition of intangibles | (3,198 | ) | (24,029 | ) | |||
| Net cash (used in) provided by investing activities: | (624,651 | ) | 145,629 | ||||
| Cash flow from financing activities: | |||||||
| Extinguishment of convertible debt | (93,827 | ) | – | ||||
| Proceeds from debt issuance | 1,250,000 | – | |||||
| Proceeds from exercise of warrants into common stock | – | 55,794 | |||||
| Issuance of common stock | 2,479,709 | 2,959,509 | |||||
| Net cash provided by financing activities | 3,635,882 | 3,015,303 | |||||
| Net increase in cash and cash equivalents | 962,578 | 1,466,614 | |||||
| Cash at beginning of period | 162,152 | 766,189 | |||||
| Cash at end of period | $ | 1,124,730 | $ | 2,232,803 | |||
| Non-cash transactions: | |||||||
| Bridge loan conversion into common stock | $ | 90,000 | $ | – | |||
| Forbearance settlement bridge loan | $ | 503,009 | $ | – | |||
| Additional warrants issued pursuant to CEO note payable | $ | 8,665 | $ | – | |||
| Conversion of preferred stock to common stock | $ | – | $ | 6,479 | |||
| Equity method investment – Helomics | $ | – | $ | 1,542,250 | |||
